Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer by Zhi-Qiang Wang et al.
Wang et al. Chin J Cancer  (2016) 35:8 
DOI 10.1186/s40880-015-0061-3
ORIGINAL ARTICLE
Phase II study of oxaliplatin combined 
with S-1 and leucovorin (SOL) for Chinese 
patients with metastatic colorectal cancer
Zhi‑Qiang Wang1,2†, Dong‑Sheng Zhang1,2†, Nong Xu3, De‑Yun Luo4, Yan‑Hong Deng5, Feng‑Hua Wang1,2, 
Hui‑Yan Luo1,2, Miao‑Zhen Qiu1,2, Yu‑Hong Li1,2* and Rui‑Hua Xu1,2*
Abstract 
Background: Fluoropyrimidine and oxaliplatin are widely used for patients with colorectal cancer. This phase II study 
was conducted to evaluate the efficacy and safety of the combination of S‑1, oxaliplatin, and leucovorin (SOL) in the 
treatment of Chinese patients with metastatic colorectal cancer (mCRC).
Methods: Eligible patients with untreated mCRC from four hospitals in China received intravenous oxaliplatin 
(85 mg/m2) on day 1, oral S‑1 twice daily (80–120 mg per day) on day 1–7, and leucovorin twice daily (50 mg per day) 
simultaneously with S‑1, every 2 weeks.
Results and discussion: Forty patients were enrolled in our study. In total, 296 cycles of SOL were administered. The 
overall response rate was 50.0%. At a median follow‑up of 27 months, progression‑free survival and overall survival 
were 7.0 months (95% confidence interval [CI] 6.0–10.6 months) and 22.2 months (95% CI 15.1–29.3 months), respec‑
tively. The most common grade 3/4 non‑hematological adverse events were diarrhea (n = 8, 20.0%), nausea (n = 3, 
7.5%), and vomiting (n = 3, 7.5%). The most common grade 3/4 hematological toxicities were thrombocytopenia 
(n = 3, 7.5%), neutropenia (n = 1, 2.5%), and abnormal alanine transaminase/aspartate transaminase levels (n = 1, 
2.5%). There was one treatment‑related death.
Conclusions: The data indicate that the SOL regimen is effective and moderately tolerated in Chinese patients with 
mCRC.
Trial registration: Clinical trial information: ChiCTR‑TNRC‑100000838
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Background
In 2010, colorectal cancer was the fifth most common 
cancer in men and the third most common cancer in 
women in China [1]. At present, the combination of 
oxaliplatin with infusional 5-fluorouracil (5-FU) and leu-
covorin (known as the FOLFOX regimen) or the combi-
nation of irinotecan with infusional 5-FU and leucovorin 
(known as the FOLFIRI regimen) are considered the 
standard first-line chemotherapeutic regimens for the 
treatment of patients with metastatic colorectal cancer 
(mCRC) [2–4]. However, the FOLFOX and FOLFIRI 
regimens are less desirable because 5-FU must be con-
tinuously infused via vascular access. To overcome the 
inconvenience of continuous infusion of 5-FU, oral fluo-
ropyrimidines, such as capecitabine, have been substi-
tuted for infusional 5-FU/leucovorin. Previous studies 
have shown that capecitabine plus oxaliplatin (CapeOX) 
was not inferior to the FOLFOX regimen [5].
S-1, a novel dihydropyrimidine dehydrogenase-inhib-
itory oral fluoropyrimidine, has been prescribed widely 
for patients with gastric cancer in eastern Asia [6–8]. 
In phase II studies, S-1, as a single agent, resulted in an 
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overall response rate (ORR) of 19%–40% after first-line 
treatment of mCRC [9–11]. Fluoropyrimidines are inte-
gral components of the treatment regimen for patients 
with mCRC. A meta-analysis by Thirion et al. [12] dem-
onstrated that 5-FU plus leucovorin improved the ORR 
and prolonged overall survival (OS) of patients with 
mCRC compared with single-agent 5-FU. A Japanese 
study [13] indicated that S-1 combined with leucovorin 
(2  weeks on and 2  weeks off) showed good efficacy in 
the first-line treatment of mCRC; however, patients in 
this study who received S-1 and leucovorin (2 weeks on 
and 2 weeks off) had a high occurrence rate of diarrhea, 
anorexia, and stomatitis. The result of a phase II study 
showed that patients who received S-1 plus leucovorin 
(1  week on and 1  week off) had a high ORR and a low 
occurrence rate of adverse reactions [14].
In an effort to achieve higher efficacy than S-1 and leu-
covorin (1  week on and 1  week off) alone and evaluate 
the safety, we carried out a phase II clinical trial with a 
regimen of oxaliplatin combined with S-1 and leucovorin 
(SOL; 1 week on and 1 week off) in previously untreated 
Chinese patients with mCRC.
Patients and methods
Eligibility
This study was approved by the ethics committee of Sun 
Yat-sen University Cancer Center. The reference num-
ber is YP2010031. Eligible patients met the following 
criteria: presence of unresectable, metastatic, and histo-
logically confirmed colorectal adenocarcinoma; adequate 
oral intake; older than 20  years; Eastern Cooperative 
Oncology Group performance status of 0–1; estimated 
life expectancy of more than 3 months; no prior chemo-
therapy or only fluoropyrimidine adjuvant chemother-
apy that was administered more than 6  months before 
enrollment, or oxaliplatin-based adjuvant chemotherapy 
that was administered more than 1  year before enroll-
ment; and at least one measurable disease by Response 
Evaluation Criteria in Solid Tumors (RECIST 1.0). Also, 
patients had to have adequate hematological, renal, and 
hepatic functions, as defined by a white blood cell count 
of 4.0  ×  109–12.0  ×  109/L, absolute granulocyte count 
≥2.0 × 109/L, platelet count ≥100 × 109/L, hemoglobin 
level ≥90 g/L, serum creatinine level less than the upper 
limit of normal, serum bilirubin level less than 1.5 times 
the upper limit of normal, serum aspartate aminotrans-
ferase, alanine aminotransferase, and alkaline phos-
phatase levels no more than 2.5 times the upper limits 
of normal (for patients with liver metastasis, less than 
five times). Finally, they had to provide written informed 
consent.
Patients were excluded from this study if they had a 
history of serious hypersensitivity to fluoropyrimidine, 
oxaliplatin, or leucovorin; an active infection; serious 
concomitant diseases or conditions (such as intestinal 
obstruction, bleeding, pulmonary fibrosis, heart fail-
ure, renal failure, or liver failure); severe ascites or pleu-
ral effusion; extensive bone metastasis; brain metastasis 
or symptoms of brain metastasis; diarrhea; or another 
synchronous cancer. We also excluded patients who 
participated in another clinical study less than 4  weeks 
previously; women who were pregnant, nursing, possi-
bly pregnant, or planning to become pregnant; and men 
intending to conceive children.
Treatment plan
Oxaliplatin 85  mg/m2 mixed with 500  mL of dextrose 
solution was administered intravenously over 3  h on 
day 1. The dosage of S-1 was determined according to 
the patient’s body surface area (BSA) as follows: BSA 
<1.25 m2, 40 mg; 1.25 m2 ≤ BSA < 1.50 m2, 50 mg; BSA 
≥1.50  m2, 60  mg. Leucovorin was given at a fixed dose 
of 25 mg. S-1 and leucovorin were administered together 
orally, twice daily from day 1 to 7, followed by a 7-day rest 
period. The treatment was repeated every 2 weeks until 
progression of the disease, the development of unaccep-
table toxicity, or patient withdrawal from the study.
Dose modifications
The doses of oxaliplatin and S-1 were adjusted when 
severe toxicities occurred. When both agents caused 
toxicities, the doses of both were reduced. The dose 
of leucovorin did not need to be reduced. Treatment 
was interrupted in the case of grade 2 or higher toxicity 
(except alopecia) and was not resumed until the toxicity 
had been resolved or alleviated to grade 0 or 1. The dose 
of oxaliplatin was reduced to 65 mg/m2 for related grades 
3–4 toxicity (or grade 2 peripheral neuropathy). The dose 
of S-1 was reduced by 20 mg/day for related grade 3 tox-
icity. The dose of oxaliplatin was reduced to 50  mg/m2 
if the same grade 3 toxicity occurred a second time. The 
dose of S-1 was reduced by 40 mg/day if the same grade 3 
toxicity occurred a second time. No dose increasing was 
permitted. Treatment was discontinued if the same grade 
3 toxicity occurred a third time or the same grade 4 tox-
icity occurred a second time, despite dose reduction. In 
addition, if the toxicity was not alleviated to grade 0 or 
1 after 4 weeks, the patient was excluded from the study.
Response and toxicity evaluation
RECIST 1.0 criteria were used to evaluate tumor 
response, and the National Cancer Institute-Common 
Toxicity Criteria for Adverse Events version 3.0 were used 
to assess toxicity. Tumor responses were evaluated every 
three cycles by three-dimensional computed tomogra-
phy or magnetic  resonance  imaging. All complete and 
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partial responses were assessed and confirmed no less 
than 4 weeks after the criteria for response were first met. 
After completion of the study, patients were followed up 
every 3 months until disease progression or death.
Statistical analysis
The primary endpoints of this study were ORR and pro-
gression-free survival (PFS). The secondary endpoints 
were safety and OS. PFS was defined as time from the ini-
tiation of treatment to the first documentation of disease 
progression or death from any cause. OS was measured 
from the start of treatment to the last follow-up or death. 
PFS and OS were estimated based on Kaplan–Meier 
plots and are presented as median values with a 95% con-
fidence interval (CI).
Simon’s optimal two-stage design was used to test the 
null hypothesis (80% statistical power and 5% signifi-
cance), the true ORR was less than 20%, against the alter-
native hypothesis, the true response rate was greater than 
40%. As predefined by the protocol, at least six responses 
were required among the first 17 assessable patients for 
the study to continue. In the second stage, 21 additional 
patients were enrolled to achieve a target sample size of 
38 assessable patients. Assuming a dropout rate of 5%, 40 
patients were initially required for the study.
Results
Patient characteristics
Between March 2010 and October 2012, 40 patients from 
four hospitals were enrolled. Patient characteristics are 
listed in Table  1. The median age was 56  years (range 
21–79  years), and most patients were men (n  =  27, 
67.5%). Twenty-three (57.5%) patients had colon can-
cer. All patients were histologically confirmed as having 
adenocarcinoma. The majority (72.5%) had moderately 
differentiated tumors. Thirty-three patients (82.5%) had 
resected primary tumors. Sixteen patients (40.0%) had 
previously received adjuvant chemotherapy. The most 
common metastatic site was the liver (n  =  24). The 
median number of metastatic organs was two (range 
1–5). PFS, OS, and safety were assessed for all patients. 
Five patients were unavailable for the response analysis 
due to severe adverse events (n = 1) and withdrawing the 
informed consent (n = 4).
Response to therapy and survival
A total of 296 treatment cycles were delivered to patients. 
The median number of treatment cycles was nine (range 
1–18). No patient had a complete response, but 20 
patients had partial responses, 12 had stable disease, and 
three had progressive disease. The ORR was 50.0% (95% 
CI 33.8%–66.2%). Tumor response rates are listed in 
Table 2.
The median follow-up time was 27  months (range 
10–48  months). The median PFS was 7.0  months (95% 
CI 6.0–10.6  months; Fig.  1a). The median OS was 
22.2 months (95% CI 15.1–29.3 months; Fig. 1b).
Safety
Safety was assessed in 40 patients based on a total of 
296 treatment cycles. Adverse events are listed in 
Table  3. Diarrhea, which was experienced by 20.0% of 
the patients, was the most common grade 3/4 adverse 
event. Neuropathy, which was experienced by 12.5% 
of the patients, was the second most common grade 
3/4 toxicity. Thrombocytopenia, nausea, and vomit-
ing, which were experienced by 7.5% of the patients, 
Table 1 Baseline demographic and  clinical characteristics 
of enrolled patients with mCRC
mCRC metastatic colorectal cancer, ECOG Eastern Cooperative Oncology Group, 
PS performance status
Characteristic No. of patients [cases (%)]
Sex
 Male 27 (67.5)
 Female 13 (32.5)
ECOG PS
 0 15 (37.5)
 1 25 (62.5)
Primary disease site
 Colon 23 (57.5)
 Rectosigmoid colon 1 (2.5)
 Rectum 16 (40.0)
Primary tumor resection
 No 7 (17.5)
 Yes 33 (82.5)
Adjuvant chemotherapy
 No 24 (60.0)
 Yes 16 (40.0)
Differentiation
 Well 1 (2.5)
 Moderate 29 (72.5)
 Poor 3 (7.5)
 Unknown 7 (17.5)
Metastatic sites
 Liver 24 (60.0)
 Lung 16 (40.0)
 Lymph nodes 10 (25.0)
 Peritoneum 8 (20.0)
 Others 4 (10.0)
No. of metastatic sites
 1 14 (35.0)
 2 18 (45.0)
 ≥3 8 (20.0)
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were the third most common grade 3/4 toxicities. 
Other non-hematologic toxic effects were usually mild 
(mostly grade 1/2) and manageable.
In total, 160 (54.0%) treatment cycles were delayed. 
Sixty (21.0%) cycles required a dose reduction of oxalipl-
atin. The causes of dose reduction of oxaliplatin included 
neuropathy, thrombocytopenia, and diarrhea. S-1 was 
reduced in 56 (19.0%) cycles because patients experi-
enced diarrhea, hand-foot syndrome, thrombocytopenia, 
and stomatitis. During the first cycle of treatment, one 
patient died because of grade 3 diarrhea and febrile neu-
tropenia with lung infection.
Table 2 The responses of  40 Chinese patients with  mCRC 
to the SOL regimen
SOL the combination of S-1, oxaliplatin, and leucovorin regimen. Other 
abbreviation as in Table 1
a 95% confidence interval of overall response rate is 33.8%–66.2%
Response No. of patients 
[cases (%)]
Complete response 0
Partial response 20 (50.0)
Stable disease 12 (30.0)
Disease control 32 (80.0)
Progression 3 (7.5)
Not evaluable 5 (12.5)
Overall responsea 20 (50.0)
Fig. 1 Kaplan‑Meier curves of progression‑free survival and overall survival for 40 Chinese patients with metastatic colorectal cancer. a The esti‑
mated progression‑free survival was 7.0 months (95% confidence interval [CI] 6.0–10.6 months). b The estimated overall survival was 22.2 months 
(95% CI 15.1–29.3 months)
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Discussion
This phase II study evaluated the efficacy and safety of 
SOL in the first-line treatment of Chinese patients with 
mCRC. The ORR was 50.0%, median PFS was 7.0 months, 
and median OS was 22.2 months. The common adverse 
events were diarrhea, neuropathy, thrombocytopenia, 
nausea, and vomiting.
FOLFOX and CapeOX are the standard regimens 
in the first-line treatment of patients with mCRC. In 
previous studies, the ORR of FOLFOX or CapeOx 
was determined to be 37%–55%, the median PFS was 
6–9.5 months, and the median OS was 16.2–20.8 months 
with these first-line treatments [2–5, 15–21]. In recent 
years, capecitabine and 5-FU can be substituted by S-1 
in the treatment of mCRC patients in Japan [22]. A 
phase II study evaluated the efficacy of the combination 
of oxaliplatin and S-1 (SOX) in the first-line treatment of 
mCRC. In this study, the ORR was 54%, the median time 
to progression (TTP) was 8.5  months, and the median 
OS was 27.2 months [23]. A phase III study also evalu-
ated the efficacy of SOX and CapeOX in the first-line 
treatment of mCRC. In this study, the ORR was 47% and 
36%, the median PFS was 8.5 and 6.7  months, and the 
median OS was 21.2 and 20.5 months, respectively [24]. 
Collectively, the efficacy data from all the previous stud-
ies are similar to the efficacy data of the SOL regimen in 
our study.
Mechanistically, the anti-tumor activity of 5-FU is con-
sidered to result from the formation of a ternary complex 
of 5-fluoro-2′-deoxyuridine-5′-monophosphate (metabo-
lite of 5-FU), thymidylate synthase, and 5,10-methylenete 
terahydrofolate (metabolite of leucovorin). This complex 
inhibits thymidylate synthase, thereby blocking DNA 
synthesis [25]. In a phase II study, the anti-tumor activity 
of S-1 was enhanced by oral leucovorin due to this mech-
anism [13]. This study showed an ORR of 57%, a median 
TTP of 6.7 months, and a median OS of 24.3 months in 
patients with mCRC treated with the combination of S-1 
and leucovorin (2 weeks on and 2 weeks off). The most 
common grade 3/4 toxicities were diarrhea (32%), ano-
rexia (21%), mucositis (20%), and neutropenia (14%). The 
toxicities first occurred during the 2nd week of treat-
ment. Given these data, the combination of S-1 and leu-
covorin (1 week on and 1 week off) may have the same 
efficacy and lower toxicity. The results of a recent phase 
II study showed that S-1 and leucovorin (1 week on and 
1  week off) produced an ORR of 53.5%, a median TTP 
of 6.5  months, and a median OS of 24.3  months in the 
first-line treatment of Mcrc [14]. It showed that the effi-
cacy of S-1 and leucovorin (1  week on and 1  week off) 
was similar to that of FOLFOX or CapeOX [2–5, 11–13, 
15–18]. The most common grade 3/4 toxicities of S-1 
and leucovorin (1 week on and 1 week off) were diarrhea 
(8.3%), anorexia (2.8%), mucositis (8.3%), and neutrope-
nia (9.4%), which were less common than the toxicities 
observed during the treatment with the S-1 and leucov-
orin (2 weeks on and 2 weeks off) regimen [13, 14].
We hypothesized that the efficacy might be improved 
when S-1 and leucovorin were combined with oxalipl-
atin. Therefore, the current study was designed to test the 
efficacy and safety of the SOL regimen for the first-line 
treatment of Chinese patients with mCRC.
In our study, diarrhea was the most common grade 3/4 
toxicity, which occurred in eight of 40 patients (20.0%). 
The high occurrence rate of diarrhea was unexpected. 
One patient died because of grade 3 diarrhea and febrile 
neutropenia with lung infection after the first cycle. 
Previous data showed that the occurrence rate of grade 
3/4 diarrhea was about 10% when patients received S-1 
and leucovorin or SOL (1 week on and 1 week off) [14]. 
The reason for the high occurrence rate of diarrhea in 
our study was unknown. It may be related to the small 
sample size or the expression of the fluoropyrimidine 
metabolic enzymes, such as dihydropyrimidine dehydro-
genase. Although peripheral neuropathy was commonly 
observed (95.0%), most cases were grade 1 and grade 2. 
The occurrence rates of other common grade 3/4 tox-
icities, such as neutropenia, anorexia, and fatigue, were 
lower than those observed in a Japanese study [26]. In 
our study, approximately 54.0% of the treatment cycles 
Table 3 The adverse events in  the 40 Chinese patients 
with mCRC treated with the SOL regimen
NCI-CTCAE National Cancer Institute-Common Terminology Criteria for 
Adverse Events, ALT/AST alanine transaminase/aspartate transaminase. Other 
abbreviations as in Tables 1 and 2
Event NCI-CTCAE grade, version 3.0 [cases 
(%)]
1 2 3
Leukopenia 7 (17.5) 7 (17.5) 0
Neutropenia 6 (15.0) 4 (10.0) 1 (2.5)
Anemia 3 (7.5) 3 (7.5) 0
Thrombocytopenia 5 (12.5) 7 (17.5) 3 (7.5)
Anorexia 19 (47.5) 8 (20.0) 0
Nausea 16 (40.0) 6 (15.0) 3 (7.5)
Vomiting 6 (15.0) 6 (15.0) 3 (7.5)
Diarrhea 5 (12.5) 9 (22.5) 8 (20.0)
Stomatitis 4 (10.0) 2 (5.0) 1 (2.5)
Constipation 4 (10.0) 0 0
Fatigue 18 (45.0) 5 (12.5) 1 (2.5)
Alopecia 29 (72.5) 6 (15.0) 0
Pigmentation 5 (12.5) 14 (35.0) 0
Hand‑foot syndrome 14 (35.0) 2 (5.0) 1 (2.5)
Neuropathy 21 (52.5) 12 (30.0) 5 (12.5)
Abnormal ALT/AST 7 (17.5) 3 (7.5) 1 (2.5)
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had to be delayed due to the toxicities. The dose of oxali-
platin was reduced in 21.0% of the cycles, and the dose 
of S-1was reduced in 19.0% of the cycles due to diarrhea 
and other toxicities.
A Japanese randomized phase II study compared SOL 
with FOLFOX in patients with untreated mCRC [26]. In 
this study, the median PFS was 9.6  months in the SOL 
group and 6.9  months in the FOLFOX group (hazard 
ratio [HR], 0.83; 95% CI 0.49–1.40), and the median OS 
was 28.5 and 25.9 months, respectively (HR, 0.91; 95% CI 
0.55–1.49). The efficacy shown in our study seemed to be 
worse than that in the Japanese study. This may be due 
to the limited sample size, the high rate of toxicities, and 
low dose density in our study.
In conclusion, the SOL regimen seems to be an effec-
tive, moderately tolerated, and convenient therapeutic 
strategy for the first-line treatment of Chinese patients 
with mCRC. A phase III study is necessary to validate the 
clinical outcomes of the SOL regimen.
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